Abstract
Acute myeloid leukemia (AML) represents a major therapeutic challenge with high relapse rates due to the persistence of chemotherapy-resistant leukemic stem cells (LSCs). To eradicate AML, a better understanding of the mechanisms that regulate LSC survival and resistance is essential. The PI3K/mTOR signaling pathway controls key signaling factors that promote the expansion and survival of chemotherapy-resistant LSCs. The mTOR complex 1 is negatively regulated by the imprinted gene, growth factor receptor-bound protein-10 (Grb10). In human AML, low Grb10 levels correlates with adverse prognosis and increased relapse rate. To study the role of Grb10 in regulating AML in vivo, we developed a HoxA9-Meis1 and MLL-AF9 driven murine AML models with maternal deletion of Grb10 (Grb10m/+). Primary and secondary recipient mice transplanted with Grb10m/+ leukemia cells displayed decreased survival (p
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
